Fig. 1 · Structure

Documents & Downloads

Galunisertib (LY2157299)

Cat. No. A11017 CAS 700874-72-2

TGF-βR Inhibitor

LY2157299 is an orally active transforming growth factor beta receptor (TGF-βR) kinase inhibitor.

In Stock

Publications for Galunisertib

4 publications citing this product

  1. Yuri Nagaoka, .et al. , Arch Biochem Biophys, 2024, Jan:751:109824 PMID: 37984759
  2. Eunji Jang, .et al. , Exp Mol Med, 2023, May;55(5):974-986 PMID: 37121972
  3. Satoshi Endo, .et al. , Nutr Res, 2019, 4 November PMID: 31767206
  4. Oguri G, .et al. , Am J Physiol Heart Circ Physiol., 2014, 307(9):H1339-52 PMID: 25172898

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Galunisertib (LY2157299) targets the TGFβ receptor pathway. In an ATP-free kinase competition-binding panel using the monohydrate, reported IC50 values were 0.172 μM for TGFβRI/ALK5, 0.0777 μM for ALK4 and 0.208 μM for TGFβR2. These binding endpoints show that activity is not exclusive to ALK5. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
TβRI (Cell-free assay) 56 nM

Cellular Effect

Cell Line Activity Value Description Reference
4T1 IC50 > 0.1 μM Inhibition of ALK5 in mouse 4T1 cells assessed as inhibition of TGFbeta1-induced luciferase activity after 24 hrs by luciferase reporter gene assay [PMID: 24786585]
HaCaT IC50 > 0.1 μM Inhibition of ALK5 in human HaCaT cells assessed as inhibition of TGFbeta1-induced luciferase activity after 24 hrs by luciferase reporter gene assay [PMID: 24786585]
Sf9 IC50 0.119 μM Inhibition of human recombinant GST-tagged ALK5 expressed in Sf9 insect cells using casein as substrate incubated for 60 mins in presence of [33P]-ATP by radiometric assay [PMID: 31299584]
Sf9 IC50 0.129 μM Inhibition of human recombinant GST-tagged ALK5 expressed in Sf9 insect cells using casein as substrate incubated for 60 mins in presence of [33P]-ATP by scintillation counting method [PMID: 31303386]
Sf9 IC50 69.4 nM Inhibition of human recombinant GST-fused ALK5 expressed in Sf9 insect cells using casein as substrate by proprietary radioisotopic protein kinase assay [PMID: 26483198]

Galunisertib (LY2157299) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Galunisertib (LY2157299) from 3 published references. In vitro models include panel of 456 wild-type and disease-relevant mutant kinases; NIH3T3 mouse fibroblasts.

Galunisertib (LY2157299) In Vitro Studies

In NIH3T3 fibroblasts, galunisertib monohydrate inhibited TGFβ1-stimulated proliferation with an IC50 of 0.40 μM (SE 0.06 μM). IC50 values exceeded 20 μM for PDGF- or bFGF-stimulated proliferation in the same assay. [1]

In a gastric-cancer scratch assay, 50 μM LY2157299 reduced wound closure by Hs746T cells over 72 h. This high-concentration migration result does not by itself establish target specificity. [2]

Growth responses depended on the tumor model. In an initial 66-model xenograft-derived clonogenic panel tested up to 10 μM, galunisertib monohydrate inhibited one model, stimulated 15 and produced no response in 50 under the authors’ criteria. A selected higher-concentration retest also contained inhibited, unchanged and stimulated samples. [3]

Kinase competition-binding profile

Biochemical assay · Panel of 456 wild-type and disease-relevant mutant kinases [1]

The ATP-free binding panel supports interaction with TGFβRI/ALK5, with stronger reported binding potency for ALK4 and additional submicromolar interactions. These non-standard three-point IC50 values are not cellular potency or enzyme catalytic IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TGFβRI (ALK5) competition bindingIC50 0.172 μM[1]
ALK4/ACVR1B competition bindingIC50 0.0777 μM[1]
TGFβR2 competition bindingIC50 0.208 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.2, 2 and 20 μM
Method
KINOMEscan competition binding against immobilized ligand, measured as kinase capture versus control
Vehicle
4% final DMSO
Reported limits
Binding incubation duration not specified in the reported panel method.
Methods and source locations

Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate

Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.

Table 1; Figure 1C; Results s2_1; Methods s4_1 (KINOMEscan)

TGFβRI (ALK5) competition binding: ATP-free KINOMEscan competition binding; three-point concentration response. — Table 1; Results s2_1; Methods s4_1 (KINOMEscan)

ALK4/ACVR1B competition binding: Same competition-binding panel, not a cellular treatment dose. — Table 1; Methods s4_1 (KINOMEscan)

TGFβR2 competition binding: Same ATP-free competition-binding panel. — Table 1; Methods s4_1 (KINOMEscan)

Growth-factor controls in fibroblast proliferation

Cell-based study · NIH3T3 mouse fibroblasts [1]

Galunisertib inhibited TGFβ1-driven proliferation while PDGF- and bFGF-driven proliferation had reported IC50 values above 20 μM. This supports pathway dependence in this assay, rather than general growth inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TGFβ1-stimulated NIH3T3 proliferationIC50 (SE) 0.40 (0.06) μM[1]
PDGF-stimulated NIH3T3 proliferationIC50 >20 μM[1]
bFGF-stimulated NIH3T3 proliferationIC50 >20 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response titration; exact full series not tabulated
Exposure duration
2 h compound pretreatment; 12–18 h after growth-factor addition, followed by 6 h thymidine labeling
Method
3H-thymidine incorporation; medium-alone and growth-factor comparison groups
Vehicle
DMSO-containing dilution medium; final well DMSO percentage not specified
Reported limits
Growth-factor concentrations and full galunisertib series not specified in this method.
Methods and source locations

Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate

Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.

Table 3; Figure 2B; Results s2_2; Methods s4_5

TGFβ1-stimulated NIH3T3 proliferation: 3H-thymidine incorporation; Table 3 specifies SE and a minimum of three assay runs. Figure 2 caption states four runs, each with 3–8 replicates. — Table 3; Figure 2B and caption; Methods s4_5

PDGF-stimulated NIH3T3 proliferation: Growth-factor specificity control in the same proliferation assay. — Table 3; Methods s4_5

bFGF-stimulated NIH3T3 proliferation: Growth-factor specificity control in the same proliferation assay. — Table 3; Methods s4_5

Variable clonogenic response in tumor xenograft-derived cells

Cell-based study · Initial panel of 66 tumor xenograft-derived samples; selected 24-model higher-concentration retest [3]

Most samples were not inhibited, and some showed growth stimulation. The first panel and selected higher-concentration retest belong to one clonogenic screening design; they are not pooled as independent samples. The separate melanoma viability panel is not included in these counts.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Response categories in initial 66-model clonogenic panelModel counts Inhibition: 1/66 (1.5%); stimulation: 15/66 (22.7%); no response: 50/66 (75.8%)[3]
Response categories in selected 24-model higher-concentration retestModel counts Inhibition: 5/24 (20.8%); stimulation: 10/24 (41.7%); no response: 9/24 (37.5%)[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.03–10.0 μM initially; 1.0–80.0 μM for selected retests
Exposure duration
Continuous exposure for 7–20 days, evaluated at maximum colony formation
Method
Soft-agar colony formation; image-based colony counts
Vehicle
0.3% DMSO solvent control
Reported limits
Per-model replicate counts not specified in the selected main-text method.
Methods and source locations

Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate

Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.

Results Sec13, first series; Figure 1a; Methods Sec3–Sec4

Response categories in initial 66-model clonogenic panel: Image-based colony counting versus 0.3% DMSO solvent control. Inhibition T/C ≤75%; no response 75% < T/C <125%; stimulation T/C ≥125%. — Results Sec13, first experimental series; Figure 1a; Methods Sec4

Response categories in selected 24-model higher-concentration retest: Selected retest; not an independent or unbiased response-rate estimate. Same colony-response criteria. — Results Sec13, first experimental series; Figure 1a; Methods Sec3–Sec4

Reduced wound closure in a gastric-cancer migration assay

Cell-based study · Hs746T gastric cancer cells, with NCI-N87 comparator cells [2]

At 50 μM, LY2157299 reduced scratch wound closure in Hs746T cells relative to the LY− group. NCI-N87 cells had little wound closure in either plotted condition. This is a migration-associated endpoint at a high test concentration; it does not alone establish target-specific inhibition or cytotoxicity independence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Scratch wound closure in Hs746T cells with LY2157299Directional comparison Reduced wound healing; P <0.05; n=20 (Figure 8 caption)[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
Wound width measured after 72 h
Method
Scratch wound-healing assay; immediate wound width used for normalization
Reported limits
Vehicle and treatment-specific final solvent percentage not reported in the migration method; n=20 is caption terminology, without an explicit biological-versus-technical replicate definition.
Methods and source locations

Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 (LY)

Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.

Methods Sec10–Sec11; Results Sec23; Figure 8e and caption

Scratch wound closure in Hs746T cells with LY2157299: Scratch assay; wound width after 72 h normalized to immediate post-scratch width. Figure 8e includes LY− and LY+ comparisons in Hs746T and NCI-N87 cells. No exact bar heights inferred. — Methods Sec11; Results Sec23; Figure 8e and caption

Galunisertib (LY2157299) In Vivo Studies

In 13 selected tumor xenograft models in nude mice, oral galunisertib monohydrate at 75 mg/kg twice daily for 14 days inhibited tumor growth in two models, produced no change in eight and stimulated growth in three under the study’s ABC response criteria. These results support model-dependent activity rather than uniform tumor suppression. [3]

Mixed tumor-growth responses in a xenograft mouse panel

Animal study · 13 selected human tumor xenograft models grown subcutaneously in nude mice; 12 mice per treatment group [3]

Galunisertib produced growth inhibition in two models, no change in eight and stimulation in three under the reported ABC criteria. The inhibited models were LXFA 737 and PRXF MRIH 1579. Selection of these models limits extrapolation to all tumors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor-growth response across 13 selected xenograft modelsModel counts Inhibition: 2/13 (15.4%); no change: 8/13 (61.5%); stimulation: 3/13 (23.1%)[3]
Range of ABC tumor-growth responsesABC −23.63% to 28.32%[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Twice daily
Treatment course
14 days
Vehicle
1% NaCMC, 0.5% SLS, 0.05% Antifoam, 0.085% PVP C-30
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Galunisertib versus vehicle
75 mg/kg per administration
Identical volume of the same formulation without galunisertibABC classification: 2/13 models inhibited, 8/13 unchanged, 3/13 stimulated.[3]
Galunisertib versus vehicle
Model: 13 selected tumor xenograft models in nude mice; 12 mice/group
Reported limits: Sex and age not specified in the selected in vivo method.
Methods and source locations

Compound reported in the paper: Galunisertib (LY2157299); Compound label in the paper: LY2157299 monohydrate

Evidence describes the reported material; no mass conversion or validation of the current Adooq lot is implied.

Methods Sec3 and Sec5; Results Sec15; Figure 5a

Tumor-growth response across 13 selected xenograft models: Area Between the Curves (ABC) compares treatment and control tumor growth. Inhibition >20%; no change −20% < ABC <20%; stimulation <−20%. Counts describe models, not individual mice. — Results Sec15; Figure 5a; Methods Sec5

Range of ABC tumor-growth responses: Negative ABC indicates growth stimulation; positive ABC indicates inhibition. — Results Sec15; Figure 5a

Galunisertib versus vehicle · Methods Sec5; Results Sec15; Figure 5a

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 700874-72-2
Applications TGF-βR Inhibitor
Formula C22H19N5O
Molecular Weight 369.4
Synonyms LY-2157299
SMILES
CC1=CC=CC(=N1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 66 mg/mL (178.65 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1%CMC-Na

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Galunisertib (LY2157299) Research References

  1. [1] Jonathan M. Yingling, William T. McMillen, Lei Yan, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor Oncotarget (2018). PMID: 29467918 DOI: 10.18632/oncotarget.23795 Source material
  2. [2] Eunji Jang, Min-Kyue Shin, Hyunki Kim, et al. Clinical molecular subtyping reveals intrinsic mesenchymal reprogramming in gastric cancer cells Experimental & Molecular Medicine (2023). PMID: 37121972 DOI: 10.1038/s12276-023-00989-z Source material
  3. [3] Armin Maier, Anne-Lise Peille, Vincent Vuaroqueaux, et al. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts Cellular Oncology (2015). PMID: 25573078 DOI: 10.1007/s13402-014-0210-8 Source material

Publications

4 publications citing this product

  1. Yuri Nagaoka, .et al. , Arch Biochem Biophys, 2024, Jan:751:109824 PMID: 37984759
  2. Eunji Jang, .et al. , Exp Mol Med, 2023, May;55(5):974-986 PMID: 37121972
  3. Satoshi Endo, .et al. , Nutr Res, 2019, 4 November PMID: 31767206
  4. Oguri G, .et al. , Am J Physiol Heart Circ Physiol., 2014, 307(9):H1339-52 PMID: 25172898

Added to your cart

View Cart Checkout
Loading...